摘要
目的:通过对相关对照研究进行Meta分析,评估绿激光前列腺汽化术治疗围术期口服抗凝药患者的疗效与安全性。方法:通过检索Pub Med、Medline、Embase、Cochrane Library、万方数据库、中国知网数据库进行检索。使用NOS文献质量评价表对纳入文献进行质量评价。统计分析两组之间在手术时间、留置导尿管时间、住院时间、Q_(max)、IPSS和剩余尿等6项指标的数据。使用Revman 5.3软件进行统计学分析。结果:最终纳入7篇文献,共包含993名患者。两组患者在前列腺体积、Q_(max)、IPSS评分和剩余尿方面比较均无统计学差异。围术期口服抗凝药组较围术期未口服抗凝药组手术时间长,但差异无统计学意义。在术后3个月,围术期未口服抗凝药组患者的IPSS评分较围术期口服抗凝药组患者低0.6分(MD=0.61,95%CI:0.19~1.04,P=0.005,I^(2)=0)。两组患者在其他观察指标方面无明显统计学差异。结论:绿激光前列腺汽化术治疗围术期口服抗凝药的前列腺增生患者安全有效。
Objective:To assess the effectiveness and safety of greenlight photoselective vaporization of the prostate(PVP)among the patients with benign prostate hyperplasia(BPH)on or off oral anticoagulation.Methods:Embase,Cochrane Library,Wan Fang Data,China National Knowledge Infrastructure(CNKI).Newcastle-Ottawa Scale(NOS)was used to assess the quality and risk of bias of each study.Six parameters(operation time,catheterization time,hospitalization time,Q_(max),IPSS and postvoid residual volume)from patients on or off anticoagulant therapy were collected.All statistical analyses were conducted with Revman V.5.3 software.Results:Totally,993 patients from 7 studies were eventually included.There were no significant differences in prostate volume,Q_(max),IPSS score and residual urine between the two groups.Perioperative operative time in oral anticoagulants group was longer than that of non-oral anticoagulants group,but the difference was not statistically significant.Meanwhile,IPSS in non-anticoagulants group was significantly reduced by 0.6 as compared with that in anticoagulants group at 3 rd month postoperation[MD 0.61,95%CI(0.19-1.04),P=0.005,I^(2)=0].However,there was no significant difference in other parameters.Conclusion:PVP is an effective and safe option for BPH patients on or off oral anticoagulants.
作者
刘巍
魏世平
李晓山
LIU Wei;WEI Shiping;LI Xiaoshan(Department of Urology,General Hospital of the Yangtze River Shipping,Wuhan 430010,China)
出处
《微创泌尿外科杂志》
2021年第3期195-201,共7页
Journal of Minimally Invasive Urology
关键词
绿激光前列腺汽化术
良性前列腺增生
抗凝药
greenlight photoselectibe vaporization of the prostate
benign prostate hyperplasia
anticoagulation
